Key facts
- This page summarizes Kevin Robert Lind's Form 4 filing for Longboard Pharmaceuticals, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 29 Oct 2024, 16:38.
Kevin Robert Lind - 25 Oct 2024 Form 4 Insider Report for Longboard Pharmaceuticals, Inc.
- Reporting relationship
- CEO, Director
- Issuer ticker
- N/A
- Reported as of
- 25 Oct 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Oct 2024, 16:38:30 UTC
- Prior SEC filing
- 13 Aug 2024
- Next SEC filing
- 13 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew J. Cronauer, Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kevin Robert Lind filed Form 4 for Longboard Pharmaceuticals, Inc. on 29 Oct 2024.
Change
- Previous filing in this sequence was filed on 13 Aug 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LBPH
transaction
Derivative
Retention Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +22,000
- Change %
- Price
- $0.000000
- Shares after
- 22,000
- Date
- 25 Oct 2024
- Ownership
- Direct
- Underlying class
- Voting Common Stock
- Underlying amount
- 22,000
- Exercise price
- $0.000000
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The retention restricted stock units ("Retention RSUs") vest in full on the earlier of October 25, 2025, or the date of the Reporting Person's Involuntary Termination (as defined in the Reporting Person's employment agreement) (such earlier date, the "Vesting Date"). The shares underlying the Retention RSUs will be issued upon vesting and release of the Retention RSUs. If the acquisition of the Issuer pursuant to the Agreement and Plan of Merger attached as Exhibit 2.1 to the Issuer's Current Report on Form 8-K filed with the SEC on October 15, 2024 (the "Merger Agreement") is completed prior to the Vesting Date, then, as of and following the Effective Time (as defined in the Merger Agreement), the Retention RSUs shall be settled via payment of an amount in cash, without interest, equal to the product of the Merger Consideration (as defined in the Merger Agreement) multiplied by the number of Retention RSUs, with such amount payable to the Reporting Person on the Vesting Date.